![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Hands IBSA Farmaceutici 483 Over CAPAs, Procedures
FDA Hands IBSA Farmaceutici 483 Over CAPAs, Procedures
IBSA Farmaceutici did not open a corrective action, as required, for a trend in adverse events involving pain and/or swelling in the knee following injection of Sinovial or other sodium hyaluronate devices, according to a Form 483.
The GMP Letter
Devices Inspections and AuditsThe GMP Letter
Upcoming Events
-
11Jul
-
18Jul
-
21Oct